Abstract: Objective To observe the incidence and management of hypertension induced by anti-angiogenic agents in patients with malignant carcinoma， and to evaluate the risk factor for hypertension. Methods 169 cancer patients treated with angiogenesis inhibition were collected from Nov. 2007 to Dec. 2013. All patients were diagnosed as malignant carcinoma by histopathology or cytology. Angiogenesis inhibition treatments included bevacizumab combined with chemotherapy， pazopanib， sorafenib， suntinib and axitinib. The incidence of hypertension was calculated and the severity of hypertension was classified according to NCI.CTC AE 3.0 criteria. The corresponding antihypertensive therapy was conducted. The risk factor for the occurrence of hypertension was evaluated by using univariate analysis and Logistic regression analysis. Results The incidence of hypertension was 29.0％ in 169 patients receiving anti-angiogenic agents， and among of which， incidence of grade Ⅲ was 44.9％. The earlist medium time from the initiation of treatment to the occurrence of hypertension was 4.5 days and that of the grade Ⅲ hypertension was 11.0 days. The hypertension was controlled well after antihypertensive treatment. No serious hypertensive crisis was observed. The risk of hypertension medical history and kidney cancer had advantages at 4.494- and 2.541-fold as independent factors for predicting hypertension with statistical differences（P＜0.05）. Conclusion The incidence of hypertension induced by anti-angiogenic agents was high. The severity of hypertension was mostly moderate， and the response to antihypertensive treatment is satisfying. Hypertension medical history and kidney cancer were independent predictor factors for the occurrence of hypertension after anti-angiogenic treatment.